Analysts think VRCA stock price could increase by 504%
Aug 12, 2025, 11:25 AM
-26.15%
What does VRCA do
Verrica Pharmaceuticals, headquartered in West Chester, Pennsylvania, develops treatments for skin diseases and went public in June 2018. Its pipeline includes YCANTH, VP-315, and VP-103 for various skin conditions.
4 analysts think VRCA stock price will increase by 504.44%. The current median analyst target is $40.80 compared to a current stock price of $6.75. The lowest analysts target is $30.30 and the highest analyst target is $52.50.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.